UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
 
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021
 
OR
 
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
COMMISSION FILE NUMBER 001-37969
 
ENDRA LIFE SCIENCES INC.
 (Exact name of registrant as specified in its charter)
 
Delaware
 
26-0579295
(State of incorporation)
 
(I.R.S. Employer Identification No.)
 
3600 Green Court, Suite 350, Ann Arbor, MI 48105-1570
(Address of principal executive office) (Zip code)
 
(734) 335-0468
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NDRA
The Nasdaq Stock Market LLC
Warrants, each to purchase one share of Common Stock
NDRAW
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
 
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
 
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 
 
As of May 17, 2021, there were 41,672,695 shares of our common stock, par value $0.0001 per share, outstanding.
 

 
 
 
TABLE OF CONTENTS
 
   
 
Page
 
   
 
 
 3
   
 
 
   
 3
   
 
 
   
 4
   
 
 
   
 5
   
 
 
   
 6
   
 
 
   
 7
   
 
 
 16
 
 
 22
 
 
 22
 
 
 
 
 
 
 23
 
 
 23
 
 
 23
 
 
 23
 
 
 23
 
 
 23
 
 
 
 23
 
 
 
 
 24
  
 
 
2
 
 
PART I - FINANCIAL INFORMATION
 
Item 1. Financial Statements
ENDRA Life Sciences Inc.
Condensed Consolidated Balance Sheets
 
 
 
March 31,
 
 
 December 31,
 
Assets
 
2021
 
 
2020
 
 Current Assets
 
(Unaudited)
 
 
 
 
Cash
 $16,842,753 
 $7,227,316 
Prepaid expenses
  776,092 
  390,800 
Inventory
  726,608 
  589,620 
Other current assets
  5,986 
  5,986 
Total Current Assets
  18,351,439 
  8,213,722 
Non-Current Assets
    
    
Fixed assets, net
  225,817 
  212,242 
Right of use assets
  321,563 
  339,012 
Total Assets
 $18,898,819 
 $8,764,976 
 
    
    
Liabilities and Stockholders’ Equity
    
    
Current Liabilities
    
    
Accounts payable and accrued liabilities
 $686,650 
 $910,183 
Lease liabilities, current portion
  79,175 
  76,480 
Total Current Liabilities
  765,825 
  986,663 
 
    
    
Long Term Debt
    
    
Loans
  28,484 
  337,084 
Lease liabilities
  252,345 
  271,908 
Total Long Term Debt
  280,829 
  608,992 
 
    
    
Total Liabilities
  1,046,654 
  1,595,655 
 
    
    
Stockholders’ Equity
    
    
Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 141.397 and 196.794 shares issued and outstanding, respectively
  1 
  1 
Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding
  - 
  - 
Common stock, $0.0001 par value; 80,000,000 shares authorized; 41,614,653 and 34,049,704 shares issued and outstanding, respectively
  4,161 
  3,404 
Additional paid in capital
  77,460,997 
  64,493,611 
Stock payable
  115,842 
  10,794 
Accumulated deficit
  (59,728,836)
  (57,338,489)
Total Stockholders’ Equity
  17,852,165 
  7,169,321 
Total Liabilities and Stockholders’ Equity
 $18,898,819 
 $8,764,976 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.  
 
 
3
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
 
 
 
Three Months Ended
 
 
Three Months Ended
 
 
 
March 31,
 
 
March 31,
 
 
 
2021
 
 
2020
 
Operating Expenses
 
 
 
 
 
 
Research and development
 $1,141,486 
 $1,518,146 
Sales and marketing
  160,935 
  114,955 
General and administrative
  1,273,418 
  1,467,745 
Total operating expenses
  2,575,839 
  3,100,846 
 
    
    
Operating loss
  (2,575,839)
  (3,100,846)
 
    
    
Other Expenses
    
    
Amortization of debt discount
  - 
  (228,568)
Gain on extinguishment of debt
  308,600 
  - 
Other income (expense)
  (2,037)
  6,617 
Total other expenses
  306,563 
  (221,951)
 
    
    
Loss from operations before income taxes
  (2,269,276)
  (3,322,797)
 
    
    
Provision for income taxes
  - 
  - 
 
    
    
Net Loss
 $(2,269,276)
 $(3,322,797)
 
    
    
Deemed dividend
  (121,071)
  - 
 
    
    
Net loss attributable to common stockholders
 $(2,390,347)
 $(3,322,797)
 
    
    
Net loss per share – basic and diluted
 $(0.06)
 $(0.29)
 
    
    
Weighted average common shares – basic and diluted
  37,772,515 
  11,508,843 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
4
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Stockholders’ Equity
 (Unaudited)
 
Three Months Ended March 31, 2020
 
Series A Convertible
 
 
Series B Convertible
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
Preferred Stock
 
 
Preferred Stock
 
 
Common stock
 
 
Additional
 
 
 
 
 
Accumulated
 
 
Stockholders'
 
 
 
 Shares
 
 
Amount
 
 
 Shares
 
 
Amount
 
 
 Shares
 
 
Amount
 
 
 Paid in Capital
 
 
Stock Payable
 
 
Deficit
 
 
 Equity
 
Balance as of December 31, 2019
  6,338.490 
 $1 
  351.711 
 $- 
  8,421,401 
 $842 
 $49,933,736 
  43,528 
  (45,217,437)
  4,760,670 
Series A Convertible Preferred Stock converted to Common Stock
  (3,896.570)
  - 
  - 
  - 
  4,520,982 
  452 
  37,471 
  (37,923)
  - 
  - 
Series B Convertible Preferred Stock converted to Common Stock
  - 
  - 
  (230.133)
  - 
  234,080 
  23 
  811 
  (835)
  - 
  - 
Common Stock issued for note conversions
  - 
  - 
  - 
  - 
  331,441 
  33 
  493,814 
  - 
  - 
  493,847 
Common Stock issued for warrant exercise
  - 
  - 
  - 
  - 
  45,101 
  5 
  39,233 
  - 
  - 
  39,238 
Fair value of vested stock options
  - 
  - 
  - 
  - 
  - 
  - 
  511,080 
  - 
  - 
  511,080 
Stock to be issued, Preferred Dividend
  - 
  - 
  - 
  - 
  - 
  - 
  (34,066)
  34,066 
  - 
  - 
Stock to be issued, Consultant
  - 
    
  - 
  - 
  - 
  - 
  - 
  40,000 
  - 
  40,000 
Net loss
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (3,322,797)
  (3,322,797)
Balance as of March 31, 2020
  2,441.920 
 $1 
  121.578 
 $- 
  13,553,005 
 $1,355 
 $50,982,080 
  78,836 
  (48,540,234)
  2,522,038 
 
Three Months Ended March 31, 2021
 
Series A Convertible
 
 
Series B Convertible
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
Preferred Stock
 
 
Preferred Stock
 
 
Common stock
 
 
Additional
 
 
 
 
 
Accumulated
 
 
Stockholders'
 
 
 
 Shares
 
 
Amount
 
 
 Shares
 
 
Amount
 
 
 Shares
 
 
Amount
 
 
 Paid in Capital
 
 
Stock Payable
 
 
Deficit
 
 
 Equity
 
Balance as of December 31, 2020
  196.794 
 $1 
  - 
 $- 
  34,049,704 
 $3,404 
 $64,493,611 
  10,795 
  (57,338,489)
  7,169,322 
Series A Convertible Preferred Stock converted to Common Stock
  (55.397)
  - 
  - 
  - 
  67,889 
  7 
  (7)
  - 
  - 
  - 
Common Stock issued for cash, net of funding costs
  - 
  - 
  - 
  - 
  3,914,217 
  391 
  9,797,902 
  - 
  - 
  9,798,293 
Common Stock issued for warrant exercise
  - 
  - 
  - 
  - 
  3,567,899 
  357 
  2,785,270 
  - 
  - 
  2,785,627 
Common stock issued for option exercise
  - 
  - 
  - 
  - 
  14,944 
  2 
  (2)
  - 
  - 
  - 
Fair value of vested stock options
  - 
  - 
  - 
  - 
  - 
  - 
  285,489 
  - 
  - 
  285,489 
Stock payable towards preference dividend
  - 
  - 
  - 
  - 
  - 
  - 
  (22,337)
  22,337 
  - 
  - 
Stock payable towards RSU's
  - 
  - 
  - 
  - 
  - 
  - 
    
  36,460 
  - 
  36,460 
Stock payable for services
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  46,250 
  - 
  46,250 
Deemed dividend
  - 
  - 
  - 
  - 
  - 
  - 
  121,071 
  - 
  (121,071)
  - 
Net loss
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (2,269,276)
  (2,269,276)
Balance as of March 31, 2021
  141.397 
 $1 
  - 
 $- 
  41,614,653 
 $4,161 
 $77,460,997 
  115,842 
  (59,728,836)
  17,852,165 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
5
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited) 
 
 
 
Three Months Ended
 
 
Three Months Ended
 
 
 
March 31,
 
 
March 31,
 
 
 
2021
 
 
2020
 
Cash Flows from Operating Activities
 
 
 
 
 
 
Net loss
 $(2,269,276)
 $(3,322,797)
Adjustments to reconcile net loss to net cash used in operating activities:
    
    
Depreciation and amortization
  31,425 
  21,586 
Common stock, options and warrants issued for services
  321,949 
  511,080 
Amortization of debt discount
  - 
  228,568 
Amortization of right of use assets
  17,449 
  15,915 
Stock payable for investor relations
  46,250 
  40,000 
Gain on extinguishment of debt
  (308,600)
  - 
Changes in operating assets and liabilities:
    
    
Increase in prepaid expenses
  (385,292)
  (256,505)
Increase in inventory
  (136,988)
  (61,493)
Decrease in other current asset
  - 
  8,750 
Decrease in accounts payable and accrued liabilities
  (223,532)
  (258,878)
Decrease in lease liability
  (16,868)
  (14,593)
Net cash used in operating activities
  (2,923,483)
  (3,088,367)
 
    
    
Cash Flows from Investing Activities
    
    
Purchases of fixed assets
  (45,000)
  (22,350)
Net cash used in investing activities
  (45,000)
  (22,350)
 
    
    
Cash Flows from Financing Activities
    
    
Proceeds from warrant exercises
  2,785,627 
  39,238 
Proceeds from issuance of common stock
  9,798,293 
  - 
Net cash provided by financing activities
  12,583,920 
  39,238 
 
    
    
Net increase (decrease) in cash
  9,615,437 
  (3,071,479)
 
    
    
Cash, beginning of period
  7,227,316 
  6,174,207 
 
    
    
Cash, end of period
 $16,842,753 
 $3,102,728 
 
    
    
Supplemental disclosures of cash items
    
    
Interest paid
 $- 
 $1,920 
Income tax paid
 $- 
 $- 
 
    
    
Supplemental disclosures of non-cash items
    
    
Conversion of convertible notes and accrued interest
 $- 
 $493,814 
Deemed dividend
 $121,071 
 $- 
Conversion of Series A Convertible Preferred Stock
 $(7)
 $(452)
Conversion of Series B Convertible Preferred Stock
 $- 
 $(23)
Stock dividend payable
 $(22,337)
 $34,066 
Right of use asset
 $321,563 
 $389,004 
Lease liability
 $331,520 
 $394,412 
   
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
6
 
 
ENDRA Life Sciences Inc.
Notes to Condensed Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Unaudited)
 
Note 1 – Nature of the Business
 
ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) has developed and is continuing to develop technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (“CT”) and magnetic resonance imaging (“MRI”) technology is unavailable or impractical.
 
ENDRA was incorporated on July 18, 2007 as a Delaware corporation.
 
Note 2 – Summary of Significant Accounting Policies
 
Use of Estimates
 
The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
 
Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.
 
The COVID-19 outbreak, which the World Health Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to issue “stay-at-home” or similar orders, and enact restrictions on the performance of “non-essential” services, public gatherings and travel.
 
The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions, the speed of the anticipated recovery, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2021 and through the date of the filing of this Quarterly Report on Form 10-Q. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.
 
Despite the Company’s efforts, the ultimate impact of COVID-19 on the Company’s business depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.
 
Principles of Consolidation
 
The Company’s consolidated financial statements include all accounts of the Company and its consolidated subsidiary and/or entities as of reporting period ending date(s) and for the reporting period(s) then ended. All inter-company balances and transactions have been eliminated.
 
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The balance sheet at December 31, 2020 has been derived from the audited financial statements at that date. For further information, refer to the financial statements and footnotes thereto included in ENDRA Life Sciences Inc. annual financial statements for the twelve months ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2021.
 
 
7
 
 
Cash and Cash Equivalents
 
The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of one year or less, when purchased, to be cash. As of March 31, 2021 and December 31, 2020, the Company had no cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
 
Inventory
 
The Company’s inventory is stated at the lower of cost or estimated net realizable value, with cost primarily determined on a weighted-average cost basis on the first-in, first-out method. The Company periodically determines whether a reserve should be taken for devaluation or obsolescence of inventory.
 
Capitalization of Fixed Assets
 
The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.
 
Leases
 
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases.” ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. At March 31, 2021 and December 31, 2020 the Company recorded a lease liability of $331,520 and $348,388, respectively.
 
Revenue Recognition
 
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASC Topic 606”). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.
 
Under ASC Topic 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to perform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC Topic 606 did not have an impact on the Company’s operations or cash flows.
 
Research and Development Costs
 
The Company follows FASB Accounting Standards Codification (“ASC”) Subtopic 730-10, “Research and Development”. Research and development costs are charged to the statement of operations as incurred. During the three months ended March 31, 2021 and 2020, the Company incurred $1,141,486 and $1,518,146 of expenses related to research and development costs, respectively.
 
Net Earnings (Loss) Per Common Share
 
The Company computes earnings per share under ASC Subtopic 260-10, “Earnings Per Share”. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. There were 6,584,146 and 10,047,010 potentially dilutive shares, which include outstanding common stock options, warrants and shares of convertible preferred stock as of March 31, 2021 and December 31, 2020, respectively.
 
 
8
 
 
The potential shares, which are excluded from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Options to purchase common stock
  3,759,417 
  3,569,707 
Warrants to purchase common stock
  2,662,204 
  6,251,103 
Shares issuable upon conversion of Series A Convertible Preferred Stock
  162,525 
  226,200 
Potential equivalent shares excluded
  6,584,146 
  10,047,010 
 
Fair Value Measurements
 
Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.
 
In accordance with ASC Topic 820, “Fair Value Measurements and Disclosures,” the Company measures certain financial instruments at fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.
 
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
 
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
 
Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
 
The carrying amounts of the Company’s financial assets and liabilities, including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities, approximate their fair values because of the short maturity of these instruments. The fair value of notes payable and convertible notes approximates their fair values since the current interest rates and terms on these obligations are the same as prevailing market rates.
 
Share-based Compensation
 
The Company’s 2016 Omnibus Incentive Plan (the “Omnibus Plan”) permits the grant of stock options and other share-based awards to its employees, consultants and non-employee members of the board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2021, the pool of shares available for issuance under the Omnibus Plan automatically increased by 1,599,570 shares, from 5,861,658 shares to 7,461,228.
 
The Company records share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period.
  
 
9
 
 
Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees of the Company is charged to expense, if applicable, in the financial statements. These options vest in the same manner as the employee options granted under the stock incentive plan as described above.
 
Going Concern
 
The Company’s financial statements are prepared using accounting principles generally accepted in the United States (“U.S. GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has limited commercial experience and had a cumulative net loss from inception to March 31, 2021 of $59,728,836. The Company had working capital of $17,585,614 as of March 31, 2021. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern. The accompanying financial statements for the period ended March 31, 2021 have been prepared assuming the Company will continue as a going concern. Although the Company’s cash resources will likely be sufficient to meet its anticipated needs during the next twelve months, the Company will require additional financing to fund its future planned operations, including research and development and commercialization of its products.
 
The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. Management’s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. As described further below under “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” the COVID-19 pandemic has impacted the Company’s business operations to some extent and is expected to continue to do so and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be required to delay, reduce the scope of, or eliminate one or more of the Company’s research and development activities or commercialization efforts or perhaps even cease the operation of its business. The ability of the Company to continue as a going concern is dependent upon its ability to successfully secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
 
Recent Accounting Pronouncements
 
The Company considered recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or in management’s opinion will not have a material impact on the Company’s present or future consolidated financial statements.
 
Note 3 – Inventory
 
As of March 31, 2021 and December 31, 2020, inventory consisted of raw materials and subassemblies to be used in the assembly of a TAEUS system. As of March 31, 2021, the Company had no orders pending for the sale of a TAEUS system. 
 
Note 4 – Fixed Assets
 
As of March 31, 2021 and December 31, 2020, fixed assets consisted of the following:
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Property, leasehold and capitalized software
 $718,902 
 $718,902 
TAEUS development and testing
  124,208 
  79,207 
Accumulated depreciation
  (617,291)
  (585,867)
Fixed assets, net
 $225,817 
 $212,242 
 
Depreciation expense for the three months ended March 31, 2021 and 2020 was $31,425 and $21,586, respectively.
 
 
 
10
 
 
Note 5 – Accounts Payable and Accrued Liabilities
 
As of March 31, 2021 and December 31, 2020, current liabilities consisted of the following:
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Accounts payable
 $447,949 
 $402,910 
Accrued payroll
  134,218 
  48,260 
Accrued bonuses
  98,733 
  369,393 
Accrued employee benefits
  5,750 
  5,750 
Insurance premium financing
  - 
  83,870 
Total
 $686,650 
 $910,183 
 
Note 6 – Bank Loans
 
U.S. SBA Paycheck Protection Program
 
In April 2020, the Company issued a U.S. Small Business Administration (“SBA”) Paycheck Protection Program Note (the “SBA Note”) to First Republic Bank (the “Lender”) for a loan in the principal amount of $308,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”) promulgated under the Coronavirus Aid, Relief and Economic Security Act of 2020, as modified by the Paycheck Protection Program Flexibility Act of 2020.
 
The Company has applied to the Lender for the SBA Loan to be forgiven and, subsequent to the period ended March 31, 2021, the Company received notice that the SBA Loan had been forgiven in full in accordance with the terms and provisions of the PPP.
 
The Company did not provide any collateral or personal guarantees for the SBA Loan, nor did the Company pay any facility charge to the government or to the Lender.
 
Toronto-Dominion Bank Loan
 
On April 27, 2020, the Company entered into a commitment loan with TD Bank under the Canadian Emergency Business Account, in the principal aggregate amount of CAD 40,000, which is due and payable upon the expiration of the initial term on December 31, 2022. This note bears interest on the unpaid balance at the rate of zero percent (0%) per annum during the initial term. Under this note no interest payments are due until January 1, 2023. Under the conditions of the loan, twenty-five percent (25%) of the loan will be forgiven if seventy-five percent (75%) is repaid prior to the initial term date.
 
Note 7 – Capital Stock
 
At March 31, 2021, the authorized capital of the Company consisted of 90,000,000 shares of capital stock, comprised of 80,000,000 shares of common stock with a par value of $0.0001 per share, and 10,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company has designated 10,000 shares of its preferred stock as Series A Convertible Preferred Stock (“Series A Preferred Stock”) and 1,000 shares of its preferred stock as Series B Convertible Preferred Stock (“Series B Preferred Stock”), and the remainder of 9,989,000 shares remain authorized but undesignated.
 
As of March 31, 2021, there were 41,614,653 shares of common stock, 141.397 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock issued and outstanding, and a stock payable balance of $115,842.
 
During the three months ended March 31, 2021, the Company issued a total of 7,564,949 shares of its common stock, as follows:
 
67,889 shares upon the conversion of 55.397 shares of its Series A Preferred Stock;
3,914,217 shares in return for aggregate net proceeds of $9,798,293 from sales of common stock;
3,567,899 shares upon warrant exercises for an aggregate exercise price of $2,785,627;
14,944 shares upon cashless option exercise.
 
 
11
 
 
At-the-Market Equity Offering Programs
 
During the three months ended March 31, 2021, the Company entered into an at-the-market equity offering sales agreement (the “2021 Ascendiant ATM Agreement”) with Ascendiant to sell shares of common stock for aggregate gross proceeds of up to $12.6 million, from time to time, through an “at-the-market” equity offering program under which Ascendiant acted as sales agent. As of March 31, 2021 under the 2021 Ascendiant ATM Agreement the Company has issued an aggregate of 3,914,217 shares of common stock in return for net proceeds of $9,798,293.
 
Note 8 – Common Stock Options and Restricted Stock Units (“RSU’s’’)
 
Common Stock Options
 
Stock options are awarded to the Company’s employees, consultants and non-employee members of the board of directors under the 2016 Omnibus Incentive Plan (the “Omnibus Plan”) and are generally granted with an exercise price equal to the market price of the Company’s common stock at the date of grant. The aggregate fair value of these stock options granted by the Company during the three months ended March 31, 2021 was determined to be $259,251 using the Black-Scholes-Merton option-pricing model based on the following assumptions: (i) volatility rate of 81% to 99%, (ii) discount rate of 0%, (iii) zero expected dividend yield, and (iv) expected life of 8-10 years. A summary of option activity under the Company’s Omnibus Plan as of March 31, 2021, and changes during the year then ended, is presented below:
 
 
 
Number of Options
 
 
Weighted Average Exercise Price
 
 
Weighted Average Remaining Contractual Term (Years)
 
Balance outstanding at December 31, 2020
  3,569,707 
 $2.13 
  7.50 
Granted
  226,000 
  1.37 
  8.61 
Exercised
  (26,395)
  - 
  - 
Forfeited
  - 
  - 
  - 
Cancelled or expired
  (9,895)
  - 
  - 
Balance outstanding at March 31, 2021
  3,759,417 
 $2.07 
  7.35 
Exercisable at March 31, 2021
  1,612,037 
 $2.71 
  6.51 
 
Restricted Stock Units
 
A restricted stock unit grants a participant the right to receive one share of common stock, following the completion of the requisite service period. RSU’s are classified as equity. Compensation cost is based on the Company’s stock price on the grant date and is recognized on a straight-line basis over the vesting period for the entire award.
 
As a cash-conserving measure taken in light of the adverse economic conditions caused by the COVID-19 pandemic, in April 2020 the Company reduced the cash salaries of members of management by 33% for the remainder of 2020, including the salaries of its named executive officers. In lieu of cash, the Company paid this portion of management salaries in the form of RSU’s (the “RSU’s”) that vested over the remainder of the year. Additionally, the Company amended its Non-Employee Director Compensation Policy to provide that its non-employee directors’ annual retainers for the second, third and fourth fiscal quarters of 2020 would also be paid in in the form of RSU’s rather than cash.
 
On April 9, 2020, the Company granted 674,019 RSU’s to non-employee directors and certain members of management. The 461,146 RSU’s granted to management vested daily over the term through March 31, 2021. The 212,873 RSU’s granted to non-employee directors vested in three equal quarterly installments on the last date of the second, third and fourth fiscal quarters of 2020. The total fair value of the RSU’s granted on April 9, 2020 was $471,813, based on the grant date closing price of $0.70 per share.
 
 
12
 
 
As of March 31, 2021 the Company had issued and vested the following RSU’s:
 
 
 
Restricted Stock
Units Outstanding
 
 
Weighted Average
Grant Date Fair Value
 
Balance Outstanding at December 31, 2020
  - 
 $- 
Granted
  674,019 
  0.70 
Vested / Released
  (674,019)
  - 
Forfeited
  - 
  - 
Cancelled or expired
  - 
  - 
Balance outstanding at March 31, 2021
  - 
 $- 
 
Note 9 – Common Stock Warrants
 
Warrant Conversions and Consent Solicitation
 
Certain holders of our warrants issued in private placements in (i) June 2018, exercisable for an aggregate of 283,337 shares of common stock, (ii) July 2019, exercisable for an aggregate of 1,910,540 shares of common stock, and (iii) December 2019, exercisable for an aggregate of 8,958,358 shares of common stock (collectively, the “Private Warrants”) indicated to the Company that they were willing to exercise their Private Warrants at reduced exercise prices. Our board of directors approved the Company’s partially waiving the exercise prices of Private Warrants to provide for reduced exercised prices which resulted in a deemed dividend. Prices were subsequently agreed upon between the Company and each exercising warrant holder, and the Company obtained stockholder approval for the issuance of an aggregate number of shares of the Company’s common stock upon the exercise of Private Warrants greater than 19.99% of the number of shares outstanding prior to any such issuance, in compliance with Nasdaq Listing Rule 5635(d).
 
During the three months ended March 31, 2021, the Company issued an aggregate of 3,567,899 shares of its common stock upon Private Warrant exercises for net proceeds of $2,785,626.
 
The following table summarizes all stock warrant activity of the Company for the three months ended March 31, 2021:
 
 
 
Number of Warrants
 
 
Weighted Average Exercise Price
 
 
Weighted Average Contractual Term (Years)
 
Balance outstanding at December 31, 2020
  6,251,103 
 $2.79 
  2.79 
Granted
  - 
  - 
  - 
Exercised
  (3,567,899)
  0.82 
  3.55 
Forfeited
  - 
  - 
  - 
Expired
  (21,000)
  - 
  - 
Balance outstanding at March 31, 2021
  2,662,204 
 $5.28 
  1.22 
Exercisable at March 31, 2021
  2,662,204 
 $5.28 
  1.22 
 
Note 10 – Commitments & Contingencies
 
Office Lease
 
Effective January 1, 2015, the Company entered into an office lease agreement with Green Court, LLC, a Michigan limited liability company, for approximately 3,657 rentable square feet of space, for the initial monthly rent of $5,986, which commenced on January 1, 2015 for an initial term of 60 months. On October 10, 2017 this lease was amended increasing the rentable square feet of space to 3,950 and the monthly rent to $7,798. On July 16, 2019, the Company exercised its option to extend the lease for an additional 5 years past the initial term originally expiring on December 31, 2019.
 
On March 15, 2021, the Company entered into an amendment to the lease, adding approximately 3,248 rentable square feet, increasing the initial monthly rent to $15,452 effective May, 2021, and extending the term of the lease to December 31, 2025.
 
The Company records the lease asset and lease liability at the present value of lease payments over the lease term. The lease typically does not provide an implicit rate; therefore, the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease payments. The Company’s discount rate for operating leases at March 31, 2021 was 10%. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection is considered probable. As a result, the Company has been recognizing rents as they become payable based on the adoption of ASC Topic 842. The weighted-average remaining lease term is 4.17 years.
 
 
13
 
 
As of March 31, 2021, the maturities of operating lease liabilities are as follows:
 
 
 
Operating Lease
 
2021
 $76,314 
2022
  104,793 
2023
  107,954 
2024 and beyond
  111,192 
Total
 $400,253 
Less: amount representing interest
  (68,733)
Present value of future minimum lease payments
  331,520 
Less: current obligations under leases
  79,175 
Long-term lease obligations
 $252,345 
 
For the three months ended March 31, 2021 and 2020, the Company incurred rent expenses of $32,191 and $30,288, respectively.
 
Employment and Consulting Agreements
 
Francois Michelon – Effective May 12, 2017, the Company entered into an amended and restated employment agreement with Francois Michelon, the Company’s Chief Executive Officer and Chairman of the board of directors and, on December 27, 2019, entered into an amendment to the employment agreement. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors’ discretion. The annual base salary in effect during the period covered by this Form 10-Q was $355,350. Under the employment agreement, Mr. Michelon is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Pursuant to Mr. Michelon’s employment agreement, in connection with the closing of the Company’s initial public offering he was granted options to purchase an aggregate 339,270 shares of common stock. The options have a weighted average exercise price of $4.96 per share of common stock and vest in three equal annual installments beginning on May 12, 2018. Upon termination without cause, any portion of Mr. Michelon’s option award scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.
 
If Mr. Michelon’s employment is terminated by the Company without cause or Mr. Michelon terminates his employment for good reason, Mr. Michelon will be entitled to receive 12 months’ continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months’ continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control).
 
Under his employment agreement, Mr. Michelon is eligible to receive benefits that are substantially similar to those of the Company’s other senior executive officers.
 
Michael Thornton – Effective May 12, 2017, the Company entered into an amended and restated employment agreement with Michael Thornton, the Company’s Chief Technology Officer and, on December 27, 2019, entered into an amendment to the employment agreement. The term of the employment agreement runs through December 31, 2020 and continues on a year-to-year basis thereafter. The employment agreement provides for an annual base salary that is subject to adjustment at the board of directors’ discretion. The annual base salary in effect during the period covered by this Form 10-K was $267,800. Under the employment agreement, Mr. Thornton is eligible for an annual cash bonus based upon achievement of performance-based objectives established by the board of directors. Pursuant to Mr. Thornton’s employment agreement, in connection with the closing of the Company’s initial public offering he was granted options to purchase an aggregate 345,298 shares of common stock. The options have a weighted average exercise price of $4.96 per share of common stock and vest in three equal annual installments beginning on May 12, 2018. Upon termination without cause, any portion of Mr. Thornton’s option award scheduled to vest within 12 months will automatically vest, and upon termination without cause within 12 months following a change of control, the entire unvested portion of the option award will automatically vest. Upon termination for any other reason, the entire unvested portion of the option award will terminate.
 
If Mr. Thornton’s employment is terminated by the Company without cause or Mr. Thornton terminates his employment for good reason, Mr. Thornton will be entitled to receive 12 months’ continuation of his current base salary and a lump sum payment equal to 12 months of continued healthcare coverage (or 24 months’ continuation of his current base salary and a lump sum payment equal to 24 months of continued healthcare coverage if such termination occurs within one year following a change in control).
 
Under his employment agreement, Mr. Thornton is eligible to receive benefits that are substantially similar to those of the Company’s other senior executive officers.
 
 
14
 
 
David Wells – On May 13, 2019, the Company entered into an employment agreement with David Wells that superseded a consulting agreement between the Company and StoryCorp Consulting, pursuant to which Mr. Wells provided services to the Company as its Chief Financial Officer. The employment agreement provides for an annual base salary of $230,000 and eligibility for an annual cash bonus to be paid based on attainment of Company and individual performance objectives to be established by the Company’s board of directors (in 2019, the amount of such cash bonus if all goals were achieved would be 30% of the base salary plus base fees paid to StoryCorp under the consulting agreement). The employment agreement also provides for eligibility to receive benefits substantially similar to those of the Company’s other senior executive officers.
 
Pursuant to the employment agreement, on May 13, 2019 Mr. Wells was granted stock options to purchase 56,000 shares of the Company’s common stock. The stock options have an exercise price of $1.38 per share, and vest in three equal annual installments beginning on the first anniversary of the grant date.
 
Litigation
 
From time to time the Company may become a party to litigation in the normal course of business. As of March 31, 2021, there were no legal matters that management believes would have a material effect on the Company’s financial position or results of operations.
 
Note 11 – Subsequent Events
 
U.S. SBA Paycheck Protection Program
 
Subsequent to the period ending March 31, 2021, the Company received notice that the SBA Loan had been forgiven in full in accordance with the terms and provisions of the PPP.
 
Common Stock Issued for Services
 
Subsequent to the period ending March 31, 2021, the Company issued 58,042 shares of its common stock, including 25,515 shares upon cashless warrant exercise and 32,527, for services valued at $74,000.
  
 
15
 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Forward-Looking Statements
 
As used in this Quarterly Report on Form 10-Q (this “Form 10-Q”), unless the context otherwise requires, the terms “we,” “us,” “our,” “ENDRA” and the “Company” refer to ENDRA Life Sciences Inc., a Delaware corporation, and its direct and indirect subsidiaries. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our historical financial statements and related notes thereto in this Form 10-Q. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this Form 10-Q regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expectations for revenues, cash flows and financial performance, the anticipated results of our development efforts and the timing for receipt of required regulatory approvals and product launches. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our limited commercial experience, limited cash and history of losses; our ability to obtain adequate financing to fund our business operations in the future; our ability to achieve profitability; our ability to develop a commercially feasible application based on our Thermo-Acoustic Enhanced Ultrasound (“TAEUS”) technology; market acceptance of our technology; uncertainties associated with COVID-19 or coronavirus, including its possible effects on our operations; results of our human studies, which may be negative or inconclusive; our ability to find and maintain development partners; our reliance on collaborations and strategic alliances and licensing arrangements; the amount and nature of competition in our industry; our ability to protect our intellectual property; potential changes in the healthcare industry or third-party reimbursement practices; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications for Food and Drug Administration (“FDA”) approval; our ability to obtain and maintain CE mark certification and secure required FDA and other governmental approvals for our TAEUS applications; our ability to comply with regulation by various federal, state, local and foreign governmental agencies and to maintain necessary regulatory clearances or approvals; and the other risks and uncertainties described in the Risk Factors section of our Annual Report on Form 10-K for the period ended December 31, 2020, as filed with the SEC on March 25, 2021, and in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of this Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
 
Available Information
 
From time to time, we use press releases, Twitter (@endralifesci) and LinkedIn (www.linkedin.com/company/endra-inc) to distribute material information. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com. Accordingly, investors should monitor these channels, in addition to our SEC filings and public conference calls and webcasts. In addition, investors may automatically receive e-mail alerts and other information about the Company by enrolling their e-mail addresses by visiting the “Email Alerts” section of our website at investors.endrainc.com. Information that is contained in and can be accessed through our website, Twitter posts and LinkedIn are not incorporated into, and do not form a part of, this Quarterly Report or any other report or document we file with the SEC.
 
Overview
 
We are leveraging experience with pre-clinical enhanced ultrasound devices to develop technology for increasing the capabilities of clinical diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (“CT”) and magnetic resonance imaging (“MRI”) technology, or other diagnostic technologies such as surgical biopsy, are unavailable or impractical.
 
In 2010, we began marketing and selling our Nexus 128 system, which combined light-based thermoacoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. Building on this expertise in thermoacoustics, we have developed a next-generation technology platform — Thermo Acoustic Enhanced Ultrasound, or TAEUS — which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of a number of significant medical conditions that currently require the use of expensive CT or MRI imaging or where imaging is not practical using existing technology. We ceased production, service support and parts for our Nexus 128 system in 2019 in order to focus our resources on the development of our TAEUS technology.
 
 
16
 
 
Unlike the near-infrared light pulses used in our legacy Nexus 128 system, our TAEUS technology uses radio frequency (“RF”) pulses to stimulate tissues, using a small fraction (less than 1%) of the energy that would be transmitted into the body during an MRI scan. The use of RF energy allows our TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals, which are detected by an external ultrasound receiver and a digital acquisition system that is part of the TAEUS system. The detected ultrasound is processed into images and other forms of data using our proprietary algorithms and displayed to complement conventional gray-scale ultrasound images.
 
We expect that the first-generation TAEUS application will be a standalone ultrasound accessory designed to cost-effectively quantify fat in the liver and stage progression of nonalcoholic fatty liver disease (“NAFLD”), which can only be achieved today with impractical surgical biopsies or MRI scans. Subsequent TAEUS offerings are expected to be implemented via a second generation hardware platform that can run multiple clinical software applications that we will offer TAEUS users for a one-time licensing fee – adding ongoing customer value to the TAEUS platform and a growing software revenue stream for our Company.
 
In April 2016, we entered into a Collaborative Research Agreement with General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center (collectively, “GE Healthcare”). Under the terms of the agreement, GE Healthcare has agreed to assist us in our efforts to commercialize our TAEUS technology for use in a fatty liver application by, among other things, providing equipment and technical advice, and facilitating introductions to GE Healthcare clinical ultrasound customers. In return for this assistance, we have agreed to afford GE Healthcare certain rights of first offer with respect to manufacturing and licensing rights for the target application. On December 16, 2020, we and GE Healthcare entered into an amendment to our agreement, extending its term to December 16, 2022.
 
Each of our TAEUS platform applications will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we intend to seek initial approval of our applications for sale in the European Union and the United States, followed by China.
 
In March 2020, we received CE mark approval for our TAEUS FLIP (Fatty Liver Imaging Probe) System. The CE marking indicates that TAEUS FLIP System complies with all applicable European Directives and Regulations in the European Union and other CE mark geographies, including the 27 EU member states.
 
In June 2020, we submitted a 510(k) Application to the FDA for our TAEUS FLIP System.
 
In March 2021, we announced an agreement with a clinical-stage biopharmaceutical company to incorporate TAEUS as an add-on technology to support the company’s patient screening and biomarker measurement during an upcoming clinical trial. We are also party to clinical evaluation agreements with several research institutions to provide additional data on our TAEUS FLIP system.
 
Financial Operations Overview
 
Revenue
 
No revenue has been generated by our TAEUS technology, which we have not commercially sold as of March 31, 2021.
 
Cost of Goods Sold
 
No cost of goods sold has been generated by our TAEUS technology, which we have not commercially sold as of March 31, 2021.
 
Research and Development Expenses
 
Our research and development expenses primarily include wages, fees and equipment for the development of our TAEUS technology platform and the proposed applications. Additionally, we incur certain costs associated with the protection of our products and inventions through a combination of patents, licenses, applications and disclosures.
 
Sales and Marketing Expenses
 
Sales and marketing expenses consist primarily of headcount and consulting costs, and marketing and tradeshow expenses. Currently, our marketing efforts are through our website and attendance of key industry meetings and conferences. In connection with the commercialization of our TAEUS applications, we are building a small sales and marketing team to train and support global ultrasound distributors, and expect to execute traditional marketing activities such as promotional materials, electronic media and participation in industry events and conferences. In September 2020, we hired a full-time sales representative in the United Kingdom and are actively adding to our sales representation and support headcount for operations in the EU.
 
 
17
 
 
General and Administrative Expenses
 
General and administrative expenses consist primarily of salaries and related expenses for our management and personnel, and professional fees, such as for accounting, consulting and legal services.
 
Critical Accounting Policies and Estimates
 
Use of Estimates
 
The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
 
Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.
 
Share-based Compensation
 
Our 2016 Omnibus Incentive Plan (the “Omnibus Plan”) permits the grant of stock options and other stock awards to our employees, consultants and non-employee members of our board of directors. Each January 1 the pool of shares available for issuance under the Omnibus Plan automatically increases by an amount equal to the lesser of (i) the number of shares necessary such that the aggregate number of shares available under the Omnibus Plan equals 25% of the number of fully-diluted outstanding shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase shares) and (ii) if the board of directors takes action to set a lower amount, the amount determined by the board. On January 1, 2021, the pool of shares issuable under the Omnibus Plan automatically increased by 1,599,570 shares from 5,861,658 shares to 7,461,228. As of March 31, 2021, there were 3,701,811 shares of common stock remaining available for issuance under the Omnibus Plan.
 
We record share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends, and the resulting charge is expensed using the straight-line attribution method over the vesting period.
 
Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees is charged to expense, if applicable, in the financial statements.
 
Debt Discount and Detachable Debt-Related Warrants
 
The Company accounts for debt discounts originating in connection with conversion features that are embedded in the notes related warrants in accordance with ASC Subtopic 470-20, Debt with Conversion and Other Options. These costs are classified on the consolidated balance sheet as a direct deduction from the debt liability. The Company amortizes these costs over the term of the securities as interest expense-debt discount in the consolidated statement of operations. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the securities to interest expense.
 
Recent Accounting Pronouncements
 
See Note 2 of the accompanying financial statements for a discussion of recently issued accounting standards.
 
Results of Operations
 
Three months ended March 31, 2021 and 2020
 
Revenue
 
We had no revenue during the three months ended March 31, 2021 and 2020.
 
 
18
 
 
Cost of Goods Sold
 
We had no cost of goods sold during the three months ended March 31, 2021 and 2020.
 
Research and Development
 
Research and development expenses were $1,141,486 for the three months ended March 31, 2021, as compared to $1,518,146 for the three months ended December 31, 2020, a decrease of $376,660, or 25%. The costs include primarily wages, fees and equipment for the development of our TAEUS product line. Research and development expenses decreased from the same period for the prior year as we completed development of our initial TAEUS product and began focusing our spending on commercialization of the product that has been developed.
 
Sales and Marketing
 
Sales and marketing expenses were $160,935 for the three months ended March 31, 2021, as compared to $114,955 for the three months ended March 31, 2020, an increase of $45,980, or 40%. The increase was primarily due to additional headcount and pre-selling activities for our TAEUS product line. Currently, our marketing efforts are through our website and attendance of key industry meetings. During the period ending March 31, 2021 we began hiring and training additional staff to support our sales efforts.
 
General and Administrative
 
Our general and administrative expenses for the three months ended March 31, 2021 were $1,273,418, compared to $1,467,745 for the three months ended March 31, 2020, a decrease of $194,327, or 13%. Our wage and related expenses for the three months ended March 31, 2021 were $512,786, compared to $647,442 for the three months ended March 31, 2020. Wage and related expenses in the three months ended March 31, 2021 included $52,230 for bonuses and $117,924 of stock compensation expense related to the issuance and vesting of options and RSU’s, compared to $66,193 for bonuses, $249,585 of stock compensation expense related to the issuance and vesting of options, for the three months ended March 31, 2020. Our professional fees, which include legal, audit, and investor relations, for the three months ended March 31, 2021 were $578,101, compared to $669,275 for the three months ended March 31, 2020.
 
Gain on Extinguishment of Debt
 
During the three months ending March 31, 2021, we received notice that the SBA Loan had been forgiven in full in accordance with the terms and provisions of the PPP, and recorded a gain on extinguishment of debt of $308,600.
 
Amortization of Debt Discount
 
During the three months ended March 31, 2020, we incurred non-cash expenses of $228,568 related to the amortization of debt discount incurred as result of our issuance of our convertible notes and warrants issued in July 2019. During the three months ended March 31, 2020, we had no such expense. 
 
Net Loss
 
As a result of the foregoing, for the three months ended March 31, 2021, we recorded a net loss of $2,269,276, compared to a net loss of $3,322,797 for the three months ended March 31, 2020.
 
Liquidity and Capital Resources
 
To date we have funded our operations primarily through private and public sales of our securities. As of March 31, 2021, we had $16,842,753 in cash.
  
As of the date of this Report, we believe that our cash on hand at March 31, 2021 will be sufficient to fund our current operations through the second quarter of 2022. We will need additional capital by such time to allow us to continue to execute our commercialization plans. We continue to evaluate and manage our capital needs to support our clinical, regulatory and operational activities and prepare for EU commercialization, and US commercialization upon FDA approval of our TAEUS product. We are considering potential financing options that may be available to us, including additional sales of our common stock through our At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, dated February 19, 2021 (the “2021 Ascendiant ATM Agreement”). However, except for 2021 Ascendiant ATM Agreement, we have no commitments to obtain any additional funds, and there can be no assurance funds will be available in sufficient amounts or on acceptable terms. If we are unable to obtain sufficient additional financing in a timely fashion and on terms acceptable to us, our financial condition and results of operations may be materially adversely affected and we may not be able to continue operations or execute our stated commercialization plan.
 
 
19
 
 
The consolidated financial statements included in this Form 10-Q have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the three months ended March 31, 2021, we incurred net losses of $2,269,276 and used cash in operations of $2,923,483. While we maintain cash balances in excess of our anticipated needs for cash for the next twelve months, it is likely that we will need to raise additional capital prior to any ability to fund operations from revenue generated from the sale of our products. The financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.
 
Operating Activities
 
During the three months ended March 31, 2021, we used $2,923,483 of cash in operating activities primarily as a result of our net loss of $2,269,276, offset by share-based compensation of $321,949, gain on extinguishment of debt of $308,600, stock payable for investor relations of $46,250, depreciation expense of $31,425, amortization of Right of Use assets of $17,449, and net changes in operating assets and liabilities of $(762,680).
 
During the three months ended March 31, 2020, we used $3,088,367 of cash in operating activities primarily as a result of our net loss of $3,322,797, offset by share-based compensation of $511,080, amortization of debt discount of $228,568, depreciation expense of $21,586, amortization of Right of Use assets of $15,915, stock payable for investor relations of $40,000, and net changes in operating assets and liabilities of $(582,719).
 
Investing Activities
 
During the three months ended March 31, 2021, we used $45,000 in investing activities related to purchases of equipment.
 
During the three months ended March 31, 2020, we used $22,350 in investing activities related to purchases of equipment.
 
Financing Activities
 
During the three months ended March 31, 2021, our financing activities provided $12,583,920, including $9,798,293 in proceeds from issuance of common stock, and $2,785,627 in proceeds from warrant exercises.
 
During the three months ended March 31, 2020, our financing activities provided $39,238, in proceeds from warrant exercises. 
 
Funding Requirements
 
We have not completed the commercialization of any of our TAEUS technology platform applications. We expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase substantially as we:
 
advance the engineering design and development of our NAFLD TAEUS application;
acquire parts and build finished goods inventory of the TAEUS FLIP system;
complete regulatory filings required for marketing approval of our NAFLD TAEUS application in the United States;
seek to hire a small internal marketing team to engage and support channel partners and clinical customers for our NAFLD TAEUS application;
expand marketing of our NAFLD TAEUS application;
advance development of our other TAEUS applications; and
add operational, financial and management information systems and personnel, including personnel to support our product development, planned commercialization efforts and our operation as a public company.
 
It is possible that we will not achieve the progress that we expect because the actual costs and timing of completing the development and regulatory approvals for a new medical device are difficult to predict and are subject to substantial risks and delays. We have no committed external sources of funds. We do not expect that our existing cash will be sufficient for us to complete the commercialization of our NAFLD TAEUS application or to complete the development of any other TAEUS application and we will need to raise substantial additional capital for those purposes. As a result, we will need to finance our future cash needs through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the section of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 25, 2021 entitled “Risk Factors”. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.
 
 
20
 
 
Until we can generate a sufficient amount of revenue from our TAEUS platform applications, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. As described below, the COVID-19 pandemic has impacted our business operations to some extent and is expected to continue to do so and, in light of the effect of such pandemic on financial markets, these impacts may include reduced access to capital. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts or perhaps even cease the operation of our business. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or applications or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.
 
Coronavirus (“COVID-19”) Pandemic
 
The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue “stay-at-home” or similar orders, and enact restrictions on the performance of “non-essential” services, public gatherings and travel.
 
Beginning in March 2020, we undertook precautionary measures intended to help minimize the risk of the virus to our employees, including requiring most employees to work remotely, pausing all non-essential travel worldwide for our employees, and limiting employee attendance at industry events and in-person work-related meetings, to the extent those events and meetings are continuing. As a cash-conserving measure taken in light of the adverse economic conditions caused by the COVID-19 pandemic, in April 2020 we reduced the cash salaries of members of management by 33% for the remainder of 2020, including the salaries of our executive officers. In lieu of cash, the Company paid this portion of management salaries in the form of restricted stock units that vested over the remainder of the year. Additionally, we amended our Non-Employee Director Compensation Policy to provide that our non-employee directors’ annual retainers for the second, third and fourth fiscal quarters of 2020 would be paid in in the form of restricted stock units rather than cash. To date we do not believe these actions have had a significant negative impact on our operations. However, these actions or additional measures we may undertake may ultimately delay progress on our developmental goals or otherwise negatively affect our business. In addition, third-party actions taken to contain its spread and mitigate its public health effects of COVID-19 may negatively affect our business. 
 
The COVID-19 pandemic has impacted our clinical trial activities. Patient visits in ongoing clinical trials have been delayed, for example, due to prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. COVID-19 has also had an effect on the business at the FDA and other health authorities by causing them to reallocate resources to addressing the pandemic, which has resulted in delays of reviews and approvals, including with respect to our NAFLD TAEUS application.
 
Off-Balance Sheet Transactions
 
At March 31, 2021, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.
  
 
21
 
 
Item 3. Quantitative and Qualitative Disclosure About Market Risk
 
As a smaller reporting company, we are not required to provide the information required by this Item 3.
 
Item 4. Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures
 
As of the end of the period covered by this Form 10-Q, management performed, with the participation of our principal executive officer and principal financial officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2021, our disclosure controls and procedures were not effective.
 
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We identified the following material weakness as of March 31, 2021: insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting.
 
To remediate our internal control weaknesses, management intends to implement the following measures, as finances allow:
 
Adding sufficient accounting personnel or outside consultants to properly segregate duties and to effect a timely, accurate preparation of the financial statements. In October 2020, we engaged a contractor to assist us with certain accounting tasks, including preparation of financial statements and periodic reports filed with the Securities and Exchange Commission.
 
Upon the hiring of additional accounting personnel or outside consultants, develop and maintain adequate written accounting policies and procedures.
 
The additional hiring is contingent upon our efforts to obtain additional funding and the results of our operations. Management expects to secure funds in the coming fiscal year but provides no assurances that it will be able to do so.
 
Changes in Internal Control over Financial Reporting
 
There were no changes to our internal control over financial reporting or in other factors that could affect these controls during the three months ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, our management is currently seeking to improve our controls and procedures in an effort to remediate the deficiency described above.
  
 
22
 
 
PART II – OTHER INFORMATION
 
Item 1. Legal Proceedings
 
We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial condition. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.
 
Item 1A. Risk Factors
 
In addition to the other information set forth in this report, you should carefully consider the factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on March 25, 2021. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by any forward-looking statements contained in this report. 
 
Item 2. Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities
 
Not applicable.
 
Item 3. Defaults Upon Senior Securities
 
Not applicable.
 
Item 4. Mine Safety Disclosures
 
Not applicable.
 
Item 5. Other Information
 
Not applicable.
 
Item 6. Exhibits
 
Exhibit Number
 
Description
 
Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on May 12, 2017)
 
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 18, 2020).
 
Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-1 (File No. 333-214724), as amended, originally filed on November 21, 2016)
 
Specimen Certificate representing shares of common stock of the Company (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (File No. 333-214724), as amended, originally filed on November 21, 2016)
 
Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 11, 2019)
 
Form of Warrant issued in December 2019 Series A Convertible Preferred Stock Offering (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on December 11, 2019)
 
Certificate of Designations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 26, 2019)
 
Form of Warrant issued in December 2019 Series B Convertible Preferred Stock Offering (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on December 26, 2019)
 
Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
 
Certification of Periodic Report by Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14a and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
 
Certification of Periodic Report by Chief Executive Officer and Chief Financial Officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.INS
 
XBRL Instance Document (filed herewith)
101.SCH
 
XBRL Taxonomy Schema (filed herewith)
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase (filed herewith)
101.LAB
 
XBRL Taxonomy Extension Label Linkbase (filed herewith)
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase (filed herewith)
 
* Indicates management compensatory plan, contract or arrangement.
  
 
23
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
ENDRA LIFE SCIENCES INC.
 
 
 
 
Date: May 17, 2021
By:
/s/ Francois Michelon
 
 
 
Francois Michelon
 
 
 
Chief Executive Officer and Chairman
(Principal Executive Officer)
 
 
 
ENDRA LIFE SCIENCES INC.
 
 
 
 
 
Date: May 17, 2021
By:
/s/ David Wells
 
 
 
David Wells
 
 
 
Chief Financial Officer
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
 
      
 
24
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more ENDRA Life Sciences Charts.
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more ENDRA Life Sciences Charts.